Mizuho Maintains Outperform on Avalo Therapeutics, Raises Price Target to $45

Mizuho analyst Joseph Catanzaro maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and raises the price target from $39 to $45.